A Retrospective Real-World Study Based on RATIONALE-307

Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Patients With Advanced Squamous NSCLC: a Retrospective Real-World Study Based on RATIONALE-307

The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.

Inclusion Criteria:

• Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion

Exclusion Criteria:

• Patients who had a documented death before study completion in the RATIONALE-307 trial